SCHEMBL3707576

SCHEMBL3707576

CC(=O)C1=C(O)C(=O)N(CCc2ccccc2)C1c1ccc(-c2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.64
ALDH1A1 P00352 6/20 0.63
HPGD P15428 2/20 0.63
ALOX15 P16050 4/20 0.63
LMNA P02545 1/20 0.63
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
TSHR P16473 2/20 0.58
POLB P06746 1/20 0.57
USP7 Q93009 1/20 0.56
MAPT P10636 1/20 0.56
HTT P42858 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
TP53 P04637 1/20 0.56
MDM2 Q00987 1/20 0.56
HSD17B10 Q99714 2/20 0.56
FPR1 P21462 1/20 0.53
TDP1 Q9NUW8 1/20 0.52
GAA P10253 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3704381 0.93 MEN1 (0.70) KDM4EALDH1A1HPGDALOX15LMNA
SCHEMBL3714403 0.92 USP7 (0.69) KDM4EALDH1A1HPGDALOX15LMNA
SCHEMBL3705035 0.91 KDM4E (0.66) KDM4EALDH1A1HPGDALOX15LMNA
SCHEMBL16904821 0.90 KDM4E (0.64) KDM4EALDH1A1HPGDALOX15LMNA
SCHEMBL3705340 0.89 MEN1 (0.78) KDM4EALDH1A1HPGDALOX15LMNA
SCHEMBL3713778 0.89 KDM4E (0.63) KDM4EALDH1A1HPGDALOX15LMNA
SCHEMBL3707667 0.87 KDM4E (0.60) KDM4EALDH1A1HPGDALOX15LMNA
SCHEMBL3706130 0.87 ALOX15 (0.62) KDM4EALDH1A1HPGDALOX15LMNA
SCHEMBL3709481 0.86 ALDH1A1 (0.66) KDM4EALDH1A1HPGDALOX15LMNA
SCHEMBL3710353 0.86 KDM4E (0.59) KDM4EALDH1A1HPGDALOX15LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO claimed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed